Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (BMS CA209 816)

June 22, 2018
https://clinicaltrials.gov/ct2/show/NCT02998528
Cancer - Lung
Principal Investigator: Andrew M Popoff, MD
lung cancer, lung, cancer, Checkmate, BMS 816
Accepting Participants